RECENT ADVANCES IN LANSOPRAZOLE SUSTAINED-RELEASE TABLET FORMULATIONS AND EVALUATION: A COMPREHENSIVE REVIEW

Suchitra Duddagi

Duddagi Suchitra Associate Professor, Department of Pharmaceutical Analysis and Quality Assurance, Vision College of Pharmaceutical Sciences and Research, RNS Colony, Boduppal, Hyderabad, Telangana, India - 500 092.

Abstract

Lansoprazole is a proton pump inhibitor (PPI) extensively used in the management of acid-related gastrointestinal disorders, including gastroesophageal reflux disease (GERD), peptic ulcer disease, Zollinger–Ellison syndrome, and Helicobacter pylori-associated infections. Despite its therapeutic efficacy, the drug exhibits several formulation challenges, such as acid instability, short plasma half-life, and variable bioavailability. These limitations have prompted extensive research into sustained-release (SR) tablet formulations aimed at prolonging drug release, enhancing gastric protection, improving patient compliance, and maintaining therapeutic plasma concentrations over extended periods. Recent advances in pharmaceutical technology have facilitated the development of innovative sustained-release systems utilizing hydrophilic and hydrophobic polymers, matrix tablets, osmotic delivery systems, multiparticulate formulations, gastro-retentive platforms, and nanotechnology-assisted approaches. These systems have demonstrated significant improvements in drug stability, controlled release behavior, pharmacokinetic performance, and clinical outcomes. Various formulation strategies employ polymers such as hydroxypropyl methylcellulose (HPMC), ethyl cellulose, Eudragit derivatives, carbopol, and sodium alginate to achieve desired release profiles. Comprehensive evaluation techniques including physicochemical characterization, dissolution studies, stability assessments, swelling behavior, kinetic modeling, and in vivo investigations are crucial for ensuring formulation quality and performance. This review critically discusses the physicochemical properties of lansoprazole, formulation approaches for sustained-release tablets, recent technological advancements, evaluation methodologies, regulatory considerations, challenges, and future perspectives. The article highlights contemporary research trends and provides a comprehensive overview for researchers and formulation scientists involved in the development of advanced oral controlled-release drug delivery systems.

Keywords: Lansoprazole, Sustained-release tablets, Proton pump inhibitors, Controlled drug delivery, Gastro-retentive systems, Pharmaceutical formulation

References

1. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006;23(Suppl 2):2-8.
2. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of proton pump inhibitors. J Neurogastroenterol Motil. 2013;19(1):25-35.
3. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K. Pharmacokinetic studies with proton pump inhibitors. Clin Pharmacokinet. 2001;40(6):411-426.
4. Colombo P, Bettini R, Santi P, De Ascentiis A, Peppas NA. Analysis of swelling and release mechanisms from drug delivery systems. J Control Release. 1996;39(2-3):231-237.
5. Yibchok-Anun S, Adisakwattana S. Stability and degradation behavior of proton pump inhibitors. Drug Dev Ind Pharm. 2010;36(4):465-472.
6. Dressman JB, Reppas C. In vitro–in vivo correlations for oral dosage forms. Eur J Pharm Sci. 2000;11(Suppl 2):S73-S80.
7. Chien YW. Novel Drug Delivery Systems. 2nd ed. New York: Marcel Dekker; 1992.
8. Siepmann J, Peppas NA. Modeling of drug release from delivery systems. Adv Drug Deliv Rev. 2012;64:163-174.
9. Nokhodchi A, Raja S, Patel P, Asare-Addo K. The role of oral controlled release matrix tablets in drug delivery systems. Bioimpacts. 2012;2(4):175-187.
10. Alderman DA. Review of cellulose ethers in hydrophilic matrix systems. Int J Pharm Tech Prod Mfr. 1984;5:1-9.
11. Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery systems. Expert Opin Drug Deliv. 2006;3(2):217-233.
12. Ghebre-Sellassie I. Multiparticulate Oral Drug Delivery. New York: Marcel Dekker; 1994.
13. Verma RK, Garg S. Osmotically controlled oral drug delivery. Drug Dev Ind Pharm. 2001;27(7):695-708.
14. Mehnert W, Mäder K. Solid lipid nanoparticles. Adv Drug Deliv Rev. 2012;64:83-101.
15. United States Pharmacopeia 47–National Formulary 42. Rockville, MD: USP Convention; 2024.
16. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous matrices. Int J Pharm. 1983;15(1):25-35.
17. International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products. Geneva; 2003.
18. Miner P Jr, Katz PO, Chen Y. Clinical efficacy of proton pump inhibitor formulations. Am J Gastroenterol. 2003;98(12):2616-2620.
19. Yu LX. Pharmaceutical quality by design. AAPS J. 2008;10(2):268-276.
20. Rathbone MJ, Hadgraft J, Roberts MS. Modified-Release Drug Delivery Technology. 2nd ed. New York: Informa Healthcare; 2008.
21. Jamzad S, Fassihi R. Role of controlled-release technologies in oral delivery. Expert Opin Drug Deliv. 2006;3(5):597-608.